您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Bevacizumab(Anti-Human VEGF,Humanized Antibody)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Bevacizumab(Anti-Human VEGF,Humanized Antibody)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
包装与价格：
包装价格(元)
1mg电议
5mg电议

产品介绍
Bevacizumab (Anti-Human VEGF, Humanized Antibody) 是一种人源化 IgG1 单克隆抗体，以高亲和力特异性结合所有 VEGF-A 亚型。
Cell linesNSCLC cell lines
Preparation methodSix NSCLC cell lines were seeded (~2,000–5,000 cells per well, depending on cell type) onto 96-well plates. After 24 h of incubation, cells were treated with erlotinib (0–20 μmol/L), bevacizumab (0–20 ng/mL) or a combination of these agents (erlotinib 1 μmol/L; bevacizumab 10 ng/mL) for 72 h in serum-containing medium. The viability was determined by MTS assay (Promega, Madison, WI) according to the manufacturer’s instructions.
Concentrations0–20 ng/mL
Incubation time72 h
文献引用
产品描述

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL[2].

It is demonstrated that the subconjunctival administration of FD006, Bevacizumab and Dexamethasone can all significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)[2]. The combination of NVP-LDE225 and Paclitaxel causes a long-lasting antitumor activity, with a tumor size of 1.64 cm3 at the end of the experiment, whereas Bevacizumab plus Paclitaxel-treated mice reaches the maximum allowed tumor size on day 84[3].

[1]. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504. [2]. Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17. [3]. Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.